ASVs	Amplicon Sequence Variants
bTMB	Blood-Tumor Mutation Burden
CI	Confidence Interval
CRP	C-reactive Protein
CT	Chemotherapy
D	Durvalumab
EVs	Extracellular Vesicles
HR	Hazard Ratio
IC	Immune Cell
ICIs	Immune checkpoint inhibitors
ITT	Intention-to-treat
KEAP1	Kelch-like ECH-associated Protein 1
LC	Lymphocyte Count
LDH	Lactate Dehydrogenase
LIPI	Lung Immune Prognostic Index
mOS	Median Overall Survival
mPFS	Median Progression-Free Survival
NA	Not Available
NC	Neutrophil Count
NCCN	National Comprehensive Cancer Network
NE	Not Estimable
NLR	Neutrophil-to-lymphocyte Ratio
NPV	Negative Predictive Value
NRF2	Nuclear Factor Erythroid 2-related Factor 2
NSCLC	Non-Small Cell Lung Cancer
NSQ NSCLC	Non-Squamous Non-Small Cell Lung Cancer
OS	Overall Survival
PFS	Progression-Free Survival
PLR	Platelet-to-Lymphocyte Ratio
SCFAs	Short-Chain Fatty Acids
SIPS	Scottish Inflammatory Prognostic Score
SQ NSCLC	Squamous Non-Small Cell Lung Cancer
STK11	Serine/Threonine Kinase 11
T	Tremelimumab
TC	Tumor Cell
TCR	T-cell Receptors
TGF-$\beta$	Transforming Growth Factor-$\beta$
TIL	Tumor-iInfiltrating T Lymphocyte
TMAO	Trimethylamine N-Oxide
TMB	Tumor Mutation Burden
TME	Tumor Immune Microenvironment
TPS	Tumor Proportion Score
tTMB	Tissue-TMB
WCC	White Cell Count
WT	Wild Type